摘要
目的评价盐酸度洛西汀对强直性脊柱炎（As）患者伴随的抑郁及疼痛、疾病活动性和功能的疗效。方法采用病例对照研究，55例伴抑郁症状的AS患者随机分为联合用药组和对照组；于基线、治疗4、12周末进行Bath强直性脊柱炎疾病活动指数（BASDAI）、功能指数（BASFI）、测量指数（BASMI）、脊柱痛、抑郁自评量表（SDS）、焦虑自评量表（SAS）、汉密尔顿抑郁量表（HAMD）评估。结果（1）治疗后联合用药组脊柱痛、BASDAI、BASFI、SDS下降，差异有统计学意义（P〈0．05），而BASMI、SAS差异无统计学意义（P〉0．05）。（2）脊柱痛和BASDAI减分率与SDS、SAS减分率正相关，BASFI减分率与SDS、HAMD减分率正相关，BASMI与SDS、SAS、HAMD无相关关系。（3）联合用药组AS症状（BASDAI和脊柱痛评分）缓解高于对照组（P〈0．01，P〈0．05），抑郁的疗效优于对照组（P〈0．01）。结论联合抗抑郁药物治疗可有效控制As患者伴随的抑郁和焦虑症状，并更好促进AS症状的临床缓解。
Objective To evaluate the effects of duloxetine on depression, anxiety, pain, disease activity and function in patients with ankylosing spondylitis （AS）. Methods A total of 55 AS patients with concurrent depression disorders were randomized into treatment and control groups. Both were given conventional therapy of AS while duloxetine was administered in treatment group. Bath ankylosing spondylitis disease activity index （BASDAI）, functional Index （BASFI） and metrology Index （BASMI）, spinal pain, self-rating anxiety scale （SAS）, self-rating depression scale （SDS） and Hamilton depression scale （HAMD） were recorded before and Weeks 4 and 8 weeks post-treatment. Results （1） Spinal pain, BASDAI, BASFI and SDS scores significantly declined by repeated measurement data analysis of variance in treatment group （P 〈 0. 05 ）. And no statistical difference existed between BASMI and SAS （ P 〉 0. 05 ）. （2） The reduced rates of spinal pain and BASDAI were positively correlated with those of SDS and SAS. And the reduced rate of BASFI was positively correlated with SDS and HAMD reduced rate. However, no relationship existed between BASMI, SDS, SAS or HAMD. （3） The remission rate of AS symptoms and depression disorders were both significantly higher in treatment group than that in control group （P 〈 0.01, P 〈 0.05 ）. Conclusion The combined regimen of duloxetine and conventional therapy is significantly effective in the treatment of AS patients with depression and anxiety.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第13期966-969,共4页
National Medical Journal of China
